ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1676

Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study

Teresa Giani1, Eve Smith2, Rolando Cimaz3, Michael Beresford4 and Christian Hedrich2, 1AOU Meyer, Florence, Italy, 2University of Liverpool, Liverpool, United Kingdom, 3ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy, 4Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom

Meeting: ACR Convergence 2020

Keywords: Neuropsychiatry, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease, it frequently follows a more severe course. Neuropsychiatric (NP) involvement in JSLE can be aggressive and significantly affect patients’ quality of life as well as disease outcomes.

The aim of this study was to describe the demographic characteristics, clinical and laboratory features of NP involvement in JSLE.

Methods: We analyzed data from JSLE patients enrolled in the UK JSLE Cohort Study between August 2006 and June 2019. Demographic (age, gender, ethnicity, family history), clinical (1997 ACR classification criteria, disease activity BILAG, SLICC, and damage index SLICC-SDI) and laboratory (ESR, CRP, CBC with diff, ANA, anti-ENA, anti-dsDNA, aCL, lipid profile, renal function, C3, C4, Ig levels, thyroid function, UA) data collected at disease onset and at last visit were analyzed.

Results: A total of 428 JSLE patients were included, with a female:male ratio of 5.4:1. The median age at diagnosis was 12.2 years (range: 0-17). A majority of JSLE patients were Caucasian (51.4%), followed by patients of South Asian (23.3%), Black African/Caribbean (16.7%), and East Asian (6.5%) descent. Patients with headaches as the only NP symptom were excluded here, because of the low specificity of this feature.

Overall, one quarter of JSLE patients (107/428, 25%) showed NP features; in 48.5% of these cases, NP symptoms were the presenting manifestation. The median age at disease onset and ethnic composition did not differ between sub-cohorts with vs without NP involvement. Most frequently recorded NP manifestations included cognitive impairment (n=45, 42%), seizures (n=21, 20%), psychotic features (n=11, 10%), peripheral nerve involvement (n=9, 8%), cerebral vasculitis (n=10, 9%), and ischaemic stroke (n=7, 6%). Headache was an accompanying manifestation in 74% of all NP-JSLE patients.

While no differences were recorded in autoantibody patterns and immune cell counts, lower platelet counts (< 100.000/mmc) were found in patients with NP involvement (p=0.02). Children with NP involvement showed both a higher number of ACR criteria (mean 4.9 vs 4.6, p=0.07) and higher SLICC scores (0.3 vs 0.2, p=0.029) at disease onset.

As compared to JSLE patients without neurological involvement, at diagnosis, patients with NP-JSLE exhibited higher disease activity (pBILAG) in the constitutional (p< 0.01) and ophthalmologic (p< 0.05) domains. At last visit, NP-JSLE patients had an increased number of ACR criteria (mean 6 vs 5.5; p< 0.001) and more damage (SLICC) (mean 1.2 vs 0.4; p< 0.001). Comparing JSLE patients with primary NP involvement to individuals who developed NP symptoms later, patients with early NP involvement exhibited more damage (SLICC) at diagnosis (mean 0.63 vs 0.05; p< 0.01) and last visit (mean 1.7 vs 0.7; p< 0.01).

Conclusion: Approximately 25% of JSLE patients enrolled in the UK JSLE Cohort Study have NP involvement. Patients with NP involvement exhibit higher disease activity and more disease-associated damage when compared to patients without NP involvement.


Disclosure: T. Giani, None; E. Smith, None; R. Cimaz, None; M. Beresford, None; C. Hedrich, None.

To cite this abstract in AMA style:

Giani T, Smith E, Cimaz R, Beresford M, Hedrich C. Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/neuropsychiatric-involvement-in-juvenile-onset-systemic-lupus-erythematosus-jsle-data-from-the-uk-jsle-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neuropsychiatric-involvement-in-juvenile-onset-systemic-lupus-erythematosus-jsle-data-from-the-uk-jsle-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology